| no |
title |
author |
magazine |
year |
volume |
issue |
page(s) |
type |
| 1 |
Acceleration of carboxylesterase-mediated activation of irinotecan to SN-38 by serum from patients with end-stage kidney disease
|
Koide, Hiroyoshi
|
|
2018
|
81 |
6 |
p. 1121-1128
|
article
|
| 2 |
A first-in-class inhibitor, MLN4924 (pevonedistat), induces cell-cycle arrest, senescence, and apoptosis in human renal cell carcinoma by suppressing UBE2M-dependent neddylation modification
|
Xu, Bo
|
|
2018
|
81 |
6 |
p. 1083-1093
|
article
|
| 3 |
Antiproteinuric effects of renin–angiotensin inhibitors in lung cancer patients receiving bevacizumab
|
Nihei, Satoru
|
|
2018
|
81 |
6 |
p. 1051-1059
|
article
|
| 4 |
A phase II study of bevacizumab and irinotecan plus alternate-day S-1 as a second-line therapy in patients with metastatic colorectal cancer: the AIRS study
|
Matsuda, Chu
|
|
2018
|
81 |
6 |
p. 1035-1041
|
article
|
| 5 |
A phase II study of modified FOLFIRINOX for chemotherapy-naïve patients with metastatic pancreatic cancer
|
Ozaka, Masato
|
|
2018
|
81 |
6 |
p. 1017-1023
|
article
|
| 6 |
A population pharmacokinetic model of cabozantinib in healthy volunteers and patients with various cancer types
|
Lacy, Steven
|
|
2018
|
81 |
6 |
p. 1071-1082
|
article
|
| 7 |
Cabazitaxel is more active than first-generation taxanes in ABCB1(+) cell lines due to its reduced affinity for P-glycoprotein
|
Duran, George E.
|
|
2018
|
81 |
6 |
p. 1095-1103
|
article
|
| 8 |
Cdc20/p55 mediates the resistance to docetaxel in castration-resistant prostate cancer in a Bim-dependent manner
|
Wu, Fei
|
|
2018
|
81 |
6 |
p. 999-1006
|
article
|
| 9 |
Combination chemotherapy with paclitaxel and oxaliplatin as first-line treatment in patients with advanced gastric cancer
|
Lan, Yan-qin
|
|
2018
|
81 |
6 |
p. 1007-1015
|
article
|
| 10 |
Correction to: Wnt/β-catenin signaling mediates the suppressive effects of diallyl trisulfide on colorectal cancer stem cells
|
Zhang, Qi
|
|
2018
|
81 |
6 |
p. 979-980
|
article
|
| 11 |
Effect of ulixertinib, a novel ERK1/2 inhibitor, on the QT/QTc interval in patients with advanced solid tumor malignancies
|
Mendzelevski, Boaz
|
|
2018
|
81 |
6 |
p. 1129-1141
|
article
|
| 12 |
IL-8 regulates the doxorubicin resistance of colorectal cancer cells via modulation of multidrug resistance 1 (MDR1)
|
Du, Jing
|
|
2018
|
81 |
6 |
p. 1111-1119
|
article
|
| 13 |
Impact of formulation on the iontophoretic delivery of the FOLFIRINOX regimen for the treatment of pancreatic cancer
|
Byrne, James D.
|
|
2018
|
81 |
6 |
p. 991-998
|
article
|
| 14 |
Multikinase inhibitor sorafenib induces skin toxicities in tumor-bearing mice
|
Tian, Aiping
|
|
2018
|
81 |
6 |
p. 1025-1033
|
article
|
| 15 |
Phase II study of cisplatin/pemetrexed combined with bevacizumab followed by pemetrexed/bevacizumab maintenance therapy in patients with EGFR-wild advanced non-squamous non-small cell lung cancer
|
Fukushima, Toshirou
|
|
2018
|
81 |
6 |
p. 1043-1050
|
article
|
| 16 |
Population exposure–response analysis of cabozantinib efficacy and safety endpoints in patients with renal cell carcinoma
|
Lacy, Steven
|
|
2018
|
81 |
6 |
p. 1061-1070
|
article
|
| 17 |
Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases
|
Fujita, Kohei
|
|
2018
|
81 |
6 |
p. 1105-1109
|
article
|
| 18 |
Survival impact of post-progression chemotherapy in advanced gastric cancer: systematic review and meta-analysis
|
Iizumi, Sakura
|
|
2018
|
81 |
6 |
p. 981-989
|
article
|
| 19 |
Wnt/β-catenin signaling mediates the suppressive effects of diallyl trisulfide on colorectal cancer stem cells
|
Zhang, Qi
|
|
2018
|
81 |
6 |
p. 969-977
|
article
|
Journal description